Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Aman Buzdar"'
Autor:
Jack Cuzick, Aman Buzdar, John F. Forbes, Anthony Howell, Elizabeth Mallon, Elena Lopez-Knowles, Richard Buus, Ivana Sestak, Mitch Dowsett
Supplementary Figure S1: Consort diagram to show the derivation of this cohort from the whole ATAC trial population.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e4e89c5fc79d7386bf0cf7e5a23a9a
https://doi.org/10.1158/1078-0432.22461231
https://doi.org/10.1158/1078-0432.22461231
Autor:
J. Jack Lee, George Wilding, Aman Buzdar, James C. Yao, David S. Hong, Suzanne E. Davis, Jun Weng, Mellanie Price, Steven I. Sherman, Chad Tang
Figure legend for supplemental figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a104c8b521082b6ddebe2b9f1263e10a
https://doi.org/10.1158/1078-0432.22464287.v1
https://doi.org/10.1158/1078-0432.22464287.v1
Autor:
Jack Cuzick, Aman Buzdar, John F. Forbes, Anthony Howell, Elizabeth Mallon, Elena Lopez-Knowles, Richard Buus, Ivana Sestak, Mitch Dowsett
Supplementary Table S1: Hazard Ratios (95% CI) and chi-square values for all recurrence and all individual genes and gene modules according to time periods in all patients, HER2-ve patients, and HER2-ve/Node-ve patients. Supplementary Table S2: Hazar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34f9b92546e2838f8fba16a7b144fca8
https://doi.org/10.1158/1078-0432.22461228
https://doi.org/10.1158/1078-0432.22461228
Autor:
Jack Cuzick, Aman Buzdar, John F. Forbes, Anthony Howell, Elizabeth Mallon, Elena Lopez-Knowles, Richard Buus, Ivana Sestak, Mitch Dowsett
Purpose: To identify the individual genes or gene modules that lead to the OncoptypeDx 21-gene recurrence score's reduced performance after 5 years and thereby identify indices of residual risk that may guide selection of patients for extended adjuva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bfacff2033f05fa450b730d4c6e5490
https://doi.org/10.1158/1078-0432.c.6524727
https://doi.org/10.1158/1078-0432.c.6524727
Autor:
J. Jack Lee, George Wilding, Aman Buzdar, James C. Yao, David S. Hong, Suzanne E. Davis, Jun Weng, Mellanie Price, Steven I. Sherman, Chad Tang
Trial Inclusion Diagram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0630d5594a23560ef3ffcefbd35cf825
https://doi.org/10.1158/1078-0432.22464293.v1
https://doi.org/10.1158/1078-0432.22464293.v1
Autor:
J. Jack Lee, George Wilding, Aman Buzdar, James C. Yao, David S. Hong, Suzanne E. Davis, Jun Weng, Mellanie Price, Steven I. Sherman, Chad Tang
Slow accruing national cooperative group trials with respect to submission year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f37fffcae8ff3acda723ab2609e8fca
https://doi.org/10.1158/1078-0432.22464290
https://doi.org/10.1158/1078-0432.22464290
Autor:
J. Jack Lee, George Wilding, Aman Buzdar, James C. Yao, David S. Hong, Suzanne E. Davis, Jun Weng, Mellanie Price, Steven I. Sherman, Chad Tang
Purpose: Slow-accruing clinical trials delay the translation of basic biomedical research, contribute to increasing health care costs, and may prohibit trials from reaching their original goals.Experimental Design: We analyzed a prospectively maintai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a491c5605c974de630bcf195b3fdc51
https://doi.org/10.1158/1078-0432.c.6525668.v1
https://doi.org/10.1158/1078-0432.c.6525668.v1
Autor:
J. Jack Lee, George Wilding, Aman Buzdar, James C. Yao, David S. Hong, Suzanne E. Davis, Jun Weng, Mellanie Price, Steven I. Sherman, Chad Tang
Supplemental Tables 1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73f616332ac44d1e092e10669cc3a705
https://doi.org/10.1158/1078-0432.22464284
https://doi.org/10.1158/1078-0432.22464284
Autor:
James N. Ingle, Richard M. Weinshilboum, Aman Buzdar, Eric D. Wieben, William R. Miller, J. Michael Dixon, Saranya Ravi, Vera J. Suman, Anthony Batzler, Gregory D. Jenkins, Brooke L. Fridley, Yvette N. Martin, Bruce W. Eckloff, Linda L. Pelleymounter, Irene Moon, Katarzyna A. Ellsworth, Liewei Wang
Supplementary Tables 1-4, Figures 1-2 from Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40802f1513bdf9448a84e941fabf4618
https://doi.org/10.1158/0008-5472.22382681.v1
https://doi.org/10.1158/0008-5472.22382681.v1
Autor:
James N. Ingle, Richard M. Weinshilboum, Aman Buzdar, Eric D. Wieben, William R. Miller, J. Michael Dixon, Saranya Ravi, Vera J. Suman, Anthony Batzler, Gregory D. Jenkins, Brooke L. Fridley, Yvette N. Martin, Bruce W. Eckloff, Linda L. Pelleymounter, Irene Moon, Katarzyna A. Ellsworth, Liewei Wang
Aromatase (CYP19) is a critical enzyme in estrogen biosynthesis and aromatase inhibitors (AI) are employed widely for endocrine therapy in postmenopausal women with breast cancer. We hypothesized that single nucleotide polymorphisms (SNPs) in the CYP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2cac2727e5c2c89858e652a48d2ab47
https://doi.org/10.1158/0008-5472.c.6500285
https://doi.org/10.1158/0008-5472.c.6500285